<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013154</url>
  </required_header>
  <id_info>
    <org_study_id>DEK-DKK1-P102</org_study_id>
    <secondary_id>DKN-01</secondary_id>
    <secondary_id>LY2812176</secondary_id>
    <secondary_id>KEYNOTE-731</secondary_id>
    <nct_id>NCT02013154</nct_id>
  </id_info>
  <brief_title>A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab</brief_title>
  <acronym>P102</acronym>
  <official_title>A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leap Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Leap Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and tolerability of DKN-01 in combination with weekly&#xD;
      paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric&#xD;
      Malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A is a Dose-Escalation Study in Participants with Relapsed or Refractory Esophageal&#xD;
      Cancer or Gastro-Esophageal Junction Tumors. Parts B, C, D and E are expansion cohorts of&#xD;
      Patients with Relapsed or Refractory Esophageal Cancer, Gastro-Esophageal Junction Tumors and&#xD;
      Gastric Adenocarcinoma.&#xD;
&#xD;
      Part F is a Dose-Escalation and Expansion Cohorts with DKN-01 + Pembrolizumab in Patients&#xD;
      with Recurrent or Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer or Gastric&#xD;
      Adenocarcinoma with Wnt Signaling Alterations.&#xD;
&#xD;
      Patients who are unable to receive paclitaxel or pembrolizumab for any reason will be allowed&#xD;
      to receive single agent DKN-01 as part of a monotherapy substudy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 5, 2014</start_date>
  <completion_date type="Actual">January 11, 2021</completion_date>
  <primary_completion_date type="Actual">July 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with dose limiting toxicities in Study Parts A and F which will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v4.03</measure>
    <time_frame>Baseline to End of cycle 1 (Part A cycle is 28 days and Part F cycle is 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse drug reactions and toxicities as evaluated by NCI CTCAE v4.03 of DKN-01 as monotherapy or in combination with paclitaxel or pembrolizumab</measure>
    <time_frame>Baseline until 30 days after last dose of study drug as assessed at a minimum of every 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response to treatment</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Disease Control Rate (ODCR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CR (DoCR)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to study completion (approximately 3 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Adenocarcinoma of the Gastroesophageal Junction</condition>
  <condition>Gastroesophageal Cancer</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DKN-01 Monotherapy Substudy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DKN-01</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>DKN-01 Monotherapy Substudy</arm_group_label>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>Part A: DKN-01 (Dose Escalation)</arm_group_label>
    <arm_group_label>Part B: DKN-01 (Dose Confirmation)</arm_group_label>
    <arm_group_label>Part C: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part D: DKN-01 (Cohort Expansion)</arm_group_label>
    <arm_group_label>Part E: DKN-01 (Cohort Expansion)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>Part F DKN-01 (Dose Escalation+Expansion)</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In advanced esophagogastric malignancies:&#xD;
&#xD;
          -  Participants with histologically confirmed recurrent or metastatic esophageal or&#xD;
             gastro-esophageal junction squamous cell or adenocarcinoma or gastric adenocarcinoma&#xD;
             with Wnt Signaling Alterations&#xD;
&#xD;
          -  Participants must be refractory or intolerant to at least one prior therapy(ies) for&#xD;
             metastatic or locally advanced disease&#xD;
&#xD;
               -  If prior therapy consisted of palliative chemoradiation therapy, it will be&#xD;
                  considered one line of therapy&#xD;
&#xD;
               -  Prior treatment with paclitaxel as part of a definitive therapy regimen is&#xD;
                  acceptable. Patients who are unable to receive paclitaxel for any reason will be&#xD;
                  allowed to receive DKN-01 as a single agent.&#xD;
&#xD;
               -  Prior treatment anti- programmed death-1 (PD-1)/ anti-PD-ligand 1 (PD-L1)&#xD;
                  monoclonal antibody (mAb) is permitted in patients provided the patient's disease&#xD;
                  is primary refractory, and the patient is not intolerant of pembrolizumab.&#xD;
                  Patients who are not eligible to receive pembrolizumab will be allowed to receive&#xD;
                  single agent DKN-01&#xD;
&#xD;
          -  Tumor tissue for mandatory evaluation&#xD;
&#xD;
          -  Must have one or more tumors measurable on radiographic imaging as defined by the&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST). Patients with evaluable but not&#xD;
             measurable disease per RECIST criteria may be enrolled with the approval of the&#xD;
             medical monitor.&#xD;
&#xD;
          -  Must be ≥18 years of age&#xD;
&#xD;
          -  Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale. A&#xD;
             performance status of 2 on the ECOG scale may be entered upon the review and approval&#xD;
             of the medical monitor&#xD;
&#xD;
          -  Disease-free of active second/secondary or prior malignancies for equal to or over 2&#xD;
             years with the exception of currently treated basal cell, squamous cell carcinoma of&#xD;
             the skin, or carcinoma &quot;in-situ&quot; of the cervix or breast&#xD;
&#xD;
          -  Acceptable liver, renal, hematologic and coagulation function&#xD;
&#xD;
          -  For men and women of child-producing potential, the use of effective contraceptive&#xD;
             methods during the study and for 6 months following the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association Class III or IV, cardiac disease, myocardial infarction&#xD;
             within the past 6 months, unstable arrhythmia&#xD;
&#xD;
          -  Fridericia-corrected QT interval (QTcF) &gt; 470 msec (female) or &gt; 450 (male), or&#xD;
             history of congenital long QT syndrome.&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, within 7 days of study&#xD;
             entry requiring systemic therapy&#xD;
&#xD;
          -  Known to be human immunodeficiency virus (HIV) positive, have hepatitis B surface&#xD;
             antigen (HBSAg), or hepatitis C antibodies (HCAb) unless HCV RNA is&#xD;
             undetected/negative.&#xD;
&#xD;
          -  Serious nonmalignant disease&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  History of osteonecrosis of the hip or have evidence of structural bone abnormalities&#xD;
             in the proximal femur on MRI scan that are symptomatic and clinically significant.&#xD;
&#xD;
          -  Systemic central nervous system (CNS) malignancy or metastasis.&#xD;
&#xD;
          -  Clinically significant peripheral neuropathy at the time of study entry. Patients with&#xD;
             pre-existing peripheral neuropathy will be allowed to receive single agent DKN-01&#xD;
&#xD;
          -  Known osteoblastic bony metastasis&#xD;
&#xD;
          -  History of known or suspected autoimmune disease with the specific exceptions of&#xD;
             vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.&#xD;
&#xD;
          -  Clinically-significant gastrointestinal disorders, such as perforation,&#xD;
             gastrointestinal bleeding, or diverticulitis.&#xD;
&#xD;
          -  Active autoimmune disease that has required systemic treatment in past 2 years (i.e.&#xD;
             with use of disease modifying agents, corticosteroids or immunosuppressive drugs).&#xD;
             Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement&#xD;
             therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of&#xD;
             systemic treatment.&#xD;
&#xD;
          -  Treatment with surgery or chemotherapy within 21 days prior to study entry (42 days&#xD;
             for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  Treatment with low dose chemotherapy concurrent with radiation within 14 days prior to&#xD;
             study entry&#xD;
&#xD;
          -  Treatment with radiation therapy within 14 days prior to study entry&#xD;
&#xD;
          -  Treatment with any other investigational agent within 30 days prior to study entry&#xD;
&#xD;
          -  Previously treated with an anti-DKK-1 therapy&#xD;
&#xD;
          -  Participants who have a history of hypersensitivity reactions to TAXOL® or other drugs&#xD;
             formulated in Cremophor® EL (polyoxyethylated castor oil). Patients who exhibit these&#xD;
             hypersensitivities will be eligible to receive single agent DKN-01.&#xD;
&#xD;
          -  Significant allergy to a pharmaceutical therapy that, in the opinion of the&#xD;
             investigator, poses an increased risk to the participant&#xD;
&#xD;
          -  Treatment with corticosteroids (≥ 10 mg per day prednisone or equivalent) or other&#xD;
             immune suppressive drugs within the 14 days prior to study entry&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Receipt of any live vaccines within 30 days before the first dose of study treatment&#xD;
             and while participating in the study&#xD;
&#xD;
          -  History of (non-infectious) pneumonitis that required steroids or current pneumonitis&#xD;
&#xD;
          -  History of interstitial lung disease&#xD;
&#xD;
          -  Intolerance or severe hypersensitivity (≥Grade 3) to pembrolizumab and/or of its&#xD;
             excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyndi Sirard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Leap Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Care Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale - New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology / Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University / VICC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC @ The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

